

Press Releases

All Years

[Advanced Search](#)

MAY 7, 2024

[Perrigo Announces Executive Transition for its Consumer Self-Care International \(CSCI\) Business](#)

MAY 1, 2024

[Perrigo Announces Quarterly Dividend](#)

APR 25, 2024

[Perrigo Receives Binding Offer to Divest its HRA Pharma Rare Diseases Business for up to €275 Million](#)

APR 23, 2024

[Perrigo to Release First Quarter 2024 Financial Results on May 7, 2024](#)

MAR 4, 2024

[Perrigo Commences Shipments of Opill® to Retailers Nationwide, Empowering Millions to Enter a New Era of Reproductive Health Access in the United States](#)

 [Video](#) ⁽¹⁾  [Photos](#) ⁽¹⁾

FEB 29, 2024

[Perrigo to Attend UBS Global Consumer and Retail Conference](#)

FEB 27, 2024

[Perrigo Reports Fourth Quarter & Fiscal Year 2023 Financial Results From Continuing Operations; Launches Investment & Efficiency Program](#)

FEB 26, 2024

[Perrigo Increases its Quarterly Dividend](#)

FEB 13, 2024

[Perrigo to Release Fourth Quarter and Fiscal Year 2023 Financial Results on February 27, 2024](#)

NOV 29, 2023

[Perrigo Announces Early Results of Cash Tender Offer for Notes](#)

NOV 10, 2023

[Perrigo Announces Cash Tender Offer for Notes](#)

NOV 7, 2023

[Perrigo Reports Third Quarter Fiscal Year 2023 Financial Results From Continuing Operations](#)

NOV 2, 2023

[Perrigo Announces Quarterly Dividend](#)

OCT 31, 2023

[Perrigo to Attend Upcoming Consumer Investor Conferences](#)

OCT 24, 2023

[Perrigo to Release Third Quarter 2023 Financial Results on November 7, 2023](#)

SEP 11, 2023

[Perrigo Announces Leadership Update](#)

AUG 24, 2023

[Perrigo to Attend Upcoming Consumer Investor Conferences](#)

AUG 8, 2023

[Perrigo Reports Second Quarter Fiscal Year 2023 Financial Results From Continuing Operations](#)

AUG 2, 2023

[PERRIGO ANNOUNCES QUARTERLY DIVIDEND](#)

JUL 25, 2023

[Perrigo to Release Second Quarter 2023 Financial Results and Present at an Industry Growth Conference](#)



JUL 13, 2023

[Perrigo Announces U.S. FDA Approval for Opill® OTC Daily Oral Contraceptive](#)

 [Photos \(1\)](#)

JUN 8, 2023

[Perrigo Appoints Patrick Lockwood-Taylor as President and CEO](#)

MAY 24, 2023

[Perrigo to Host 1x1 Investor Meetings at the 23rd Annual Oppenheimer Consumer Growth & E-Commerce Conference](#)

MAY 16, 2023

[PERRIGO ANNOUNCES U.S. FDA APPROVAL FOR NICOTINE COATED MINT LOZENGE](#)

MAY 10, 2023

[FDA Joint Advisory Committee Votes in Favor of Perrigo's Opill® Daily Oral Contraceptive for OTC Use](#)

Show per page

[«](#) [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [...](#) [38](#) [»](#)



<https://investor.perrigo.com/press-releases?l=25&o=50>